12月31日，港股的微创心通－Ｂ(02160.HK)股价涨势强劲，截至收盘，涨幅为14.15%，报1.21港元/股。该股今日大幅异动，驱动力源于公司核心产品临床数据惊艳、海外业务爆发式增长带来的多重利好共振。12月30日，微创心通发布公告宣布，其联营公司4C Medical Technologies,Inc.开发的AltaValveTM经导管二尖瓣置换医疗器械早期可行性研究一年随访结果已正式公布。...
Source Link12月31日，港股的微创心通－Ｂ(02160.HK)股价涨势强劲，截至收盘，涨幅为14.15%，报1.21港元/股。该股今日大幅异动，驱动力源于公司核心产品临床数据惊艳、海外业务爆发式增长带来的多重利好共振。12月30日，微创心通发布公告宣布，其联营公司4C Medical Technologies,Inc.开发的AltaValveTM经导管二尖瓣置换医疗器械早期可行性研究一年随访结果已正式公布。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.